GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:24 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:24 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2018.
Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover
by Zacks Equity Research
Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.
AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.
Top Ranked Income Stocks to Buy for February 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 27th:
Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron (REGN) disagree with a jury verdict in favor of Amgen upholding the validity of two patents related to Repatha.
The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto
Top Ranked Income Stocks to Buy for February 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, February 26th:
Kick the Can Entertains the Anglo Masses: Global Week Ahead
by John Blank
"Metaphorically, the phrase means??to defer conclusive action with a short-term solution."
Novartis In-Licenses Rights to Heart Candidate From Ionis
by Zacks Equity Research
Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.
Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and a revenue beat in Q4.
Top Ranked Income Stocks to Buy for February 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 22nd
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Merck Gets Priority Review for Keytruda in Third-Line SCLC
by Zacks Equity Research
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
by Zacks Equity Research
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
by Zacks Equity Research
Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
New Strong Buy Stocks for February 19th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Top Ranked Growth Stocks to Buy for February 15th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 15th
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
by Zacks Equity Research
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up
by Zacks Equity Research
Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
New Strong Buy Stocks for February 14th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Top Ranked Income Stocks to Buy for February 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 14th
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.